{
    "Trade/Device Name(s)": [
        "Stratus\u00ae CS Acute Care\u2122 D-Dimer assay",
        "Stratus\u00ae CS Acute Care\u2122 DDMR"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K110303",
    "Predicate Device Reference 510(k) Number(s)": [
        "K093626"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "April 20, 2011",
    "Summary Letter Received Date": "April 21, 2011",
    "Submission Date": "April 19, 2011",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/Fibrin Degradation Products Assay"
    ],
    "Analyte Class(es)": [
        "hematology",
        "coagulation"
    ],
    "Analyte(s)": [
        "D-dimer",
        "cross-linked fibrin degradation products"
    ],
    "Specimen Type(s)": [
        "Citrated plasma",
        "Heparinized plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Stratus\u00ae CS analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Radial Partition Immunoassay (RPIA)",
        "two-site sandwich immunoassay",
        "enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Stratus CS Acute Care D-Dimer assay for quantitative measurement of D-dimer in plasma to aid diagnosis of VTE and exclude PE",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative measurement of cross-linked fibrin degradation products (D-dimer) in human citrated or heparinized plasma on the Stratus CS analyzer, used to aid diagnosis of VTE and to exclude PE in conjunction with a non-high clinical pretest probability assessment model",
    "fda_folder": "Hematology"
}